Monitored Cell Transplant for Diabetes

About Minutia

Minutia is a private, preclinical-stage biotech founded in 2019 and based in San Francisco, focused on a transformative cell therapy for diabetes. The company is developing an implantable device containing insulin-producing cells equipped with nanosensors, designed to provide both therapeutic function and real-time monitoring of graft health and performance. It has secured significant non-dilutive funding from prestigious organizations like CIRM, NIH, and JDRF, and is led by CEO Katy Digovich with industry veteran Dan Bradbury as Chairman. Minutia's approach seeks to address key limitations in current islet cell transplantation, such as graft failure and the need for invasive monitoring.

Therapeutic Areas

Other Diabetes (Type 1) Drugs